Ganetespib, an inhibitor of HSP90, has been tested on NSCLC independently and in combination with crizotinib and other ALK inhibitors, showing improved anti-tumor effects both in vitro and in vivo, as compared to ALK inhibition alone [92]. The gene discussed is ALK; the disease is neoplasm.